Skip to main content
. Author manuscript; available in PMC: 2023 Nov 15.
Published in final edited form as: Clin Cancer Res. 2023 May 15;29(10):1969–1983. doi: 10.1158/1078-0432.CCR-22-2254

Figure 6. FST promotes chemoresistance and reduces apoptosis in vivo.

Figure 6.

A. Western blotting for FST in SKOV3 cells expressing CRISPR-Cas9 and FST gRNA#1 or gRNA #2. B and C. AnnexinV/PI apoptosis assay and total apoptotic cell number for wild type (WT) and SKOV3-FST-KO cells treated with or without 4 nM taxol. D. Cell counts of SKOV3-FST-KO cells treated with or without 4 nM taxol. E. Survival plots of NSG mice (N=10) injected with 150,000 FST-KO SKOV3 or control cells into the intraperitoneal cavity. Mice received 3 doses of 10mg/kg doses of intraperitoneal Paclitaxel at days 7, 14 and 21. F. Tumor volumes of xenografted SKOV3 FST-KO or Mock cells over 38 days (N=3). **P<0.01, ***P<0.001, ****P<0.0001.